German Federal Ministry of Education and Research Invests in New TB Treatments
Every year, more than ten million people worldwide contract tuberculosis (TB) and in 2017, 1.6 million people died as a
News
Press Releases
Tuberculosis, Among the Oldest Infectious Diseases, Is Now the World’s Deadliest – It’s Time to Invest in Solutions
GENEVA (May 22, 2019) – This week at the Seventy-second World Health Assembly, TB Alliance is joining our partners in global health
New Research on Drug-Resistant TB Treatment Presented at ATS 2019
Two of TB Alliance’s academic collaborators presented findings from scientific research related to drug-resistant forms of tuberculosis at the American Thoracic
TB Alliance and Partners Form Multidisciplinary Center for Translational TB Drug Research
NEW YORK, NY (May 9, 2019)—The National Institute of Allergy and Infectious Diseases (NIAID) has awarded TB Alliance a Center
Joint Statement on Universal Health Coverage and TB Research
Joint Statement for Multi-stakeholder Hearing on UHC: Product Development Partnerships “We face a collective challenge in ensuring that everyone—regardless where
A Conversation with Karl Hofmann
We spoke with Karl Hofmann, president and CEO of Population Services International (PSI), to hear about his time serving as
TB Alliance and Mylan Announce Global Collaboration to Commercialize Investigational Drug Pretomanid as Part of Two Regimens to Treat Tuberculosis
NEW YORK, HERTFORDSHIRE, England and PITTSBURGH – April 18, 2019 – Non-profit drug developer, TB Alliance, and pharmaceutical company, Mylan
Statement on Building a Tuberculosis Free World: The Lancet Commission on Tuberculosis
March 20, 2019 – Building a Tuberculosis Free World: The Lancet Commission on Tuberculosis, released today, outlines what is needed
TB Medicine Pretomanid Enters Regulatory Review Process in the United States
NEW YORK, NY (March 8, 2019)—TB Alliance’s new drug application (NDA) for the novel tuberculosis (TB) drug candidate pretomanid has
Compound Studied in TB to be Evaluated in the Treatment of Leishmaniasis
NEW YORK (February 5, 2019) – TB Alliance applauds the Wellcome Trust’s commitment of over £10 million to the Drugs